Patents by Inventor Zhichang Xu
Zhichang Xu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240109056Abstract: The present disclosure provides a composite ionic liquid and a preparation method and a use thereof. A first aspect of the present disclosure provides a preparation method of a composite ionic liquid, where an ammonium salt, a first metal salt, a second metal salt, and a third metal salt are sequentially added into a reactor for performing a reaction under different conditions, and the composite ionic liquid is obtained after the reaction is finished. The composite ionic liquid prepared by the method may be used as a catalyst to catalyze an alkylation reaction of isoparaffin with C4 olefin to obtain alkylated oil, which has the advantages of high catalytic activity, long catalytic life, low consumption, and better distribution of the resulting alkylated oil, etc, and thereby significantly reducing the production costs and improving the quality of the resulted alkylated oil.Type: ApplicationFiled: January 19, 2023Publication date: April 4, 2024Inventors: Tao ZHENG, Rui ZHANG, Zhichang LIU, Haiyan LIU, Xianghai MENG, Chunming XU
-
Patent number: 11883476Abstract: The present invention provides a vaccine for canine Lyme disease and methods of making and using the vaccine alone, or in combinations with other protective agents.Type: GrantFiled: December 3, 2018Date of Patent: January 30, 2024Assignee: Intervet Inc.Inventors: Rhonda LaFleur, Jennifer C. Dant, Mark A. Mogler, Steven M. Callister, Zhichang Xu
-
Patent number: 11730809Abstract: The present invention provides new multivalent vaccines for felines. The present invention also provides methods of making and using the multivalent vaccines alone or in combinations with other protective agents.Type: GrantFiled: September 29, 2021Date of Patent: August 22, 2023Assignee: Intervet Inc.Inventors: Zhichang Xu, Rhonda LaFleur, Ian Tarpey
-
Publication number: 20230012140Abstract: The present invention is drawn to new oral live canine parainfluenza virus vaccines and related multivalent vaccines. Methods of using the vaccine alone or in combination with one or more other protective immunogens in multivalent vaccines are also provided.Type: ApplicationFiled: December 17, 2020Publication date: January 12, 2023Applicant: Intervet Inc.Inventors: Rhonda L. LaFleur, Jennifer C. Dant, Ian Tarpey, Zhichang Xu
-
Publication number: 20220008532Abstract: The present invention provides new multivalent vaccines for felines. The present invention also provides methods of making and using the multivalent vaccines alone or in combinations with other protective agents.Type: ApplicationFiled: September 29, 2021Publication date: January 13, 2022Applicant: Intervet Inc.Inventors: Zhichang Xu, Rhonda LaFleur, Ian Tarpey
-
Patent number: 11167027Abstract: The present invention provides new multivalent vaccines for felines. The present invention also provides methods of making and using the multivalent vaccines alone or in combinations with other protective agents.Type: GrantFiled: November 5, 2018Date of Patent: November 9, 2021Assignee: Intervet Inc.Inventors: Zhichang Xu, Rhonda LaFleur, Ian Tarpey
-
Publication number: 20200289634Abstract: The present invention provides a vaccine for canine Lyme disease and methods of making and using the vaccine alone, or in combinations with other protective agents.Type: ApplicationFiled: December 3, 2018Publication date: September 17, 2020Applicant: Intervet Inc.Inventors: Rhonda LaFleur, Jennifer C. Dant, Mark A. Mogler, Steven M. Callister, Zhichang Xu
-
Publication number: 20200254088Abstract: The present invention provides new multivalent vaccines for felines. The present invention also provides methods of making and using the multivalent vaccines alone or in combinations with other protective agents.Type: ApplicationFiled: November 5, 2018Publication date: August 13, 2020Applicant: Intervet Inc.Inventors: Zhichang Xu, Rhonda LaFleur, Ian Tarpey
-
Patent number: 9562079Abstract: The instant invention provides an immunogenic composition comprising an antigenic fragment of OspA protein of Borrelia burgdorferi and a chimeric protein containing antigenic fragments of different phylotypes of OspC protein of Borrelia burgdorferi. Vaccines incorporating the immunogenic composition of the invention, as well as methods of preventing Lyme disease in dogs and/or protecting dogs from Lyme disease using the vaccines are also provided.Type: GrantFiled: April 17, 2013Date of Patent: February 7, 2017Assignees: Zoetis Services LLC, Virginia Commonwealth UniversityInventors: Robert M. Lohse, Patrick F. M. Meeus, Jason J. Millership, Zhichang Xu, Richard Thomas Marconi, Christopher G. Earnhart
-
Publication number: 20160083435Abstract: The instant invention provides an immunogenic composition comprising an antigenic fragment of OspA protein of Borrelia burgdorferi and a chimeric protein containing antigenic fragments of different phylotypes of OspC protein of Borrelia burgdorferi. Vaccines incorporating the immunogenic composition of the invention, as well as methods of preventing Lyme disease in dogs and/or protecting dogs from Lyme disease using the vaccines are also provided.Type: ApplicationFiled: April 17, 2013Publication date: March 24, 2016Inventors: Robert M. Lohse, Patrick F. M. Meeus, Jason J. Millership, Zhichang Xu, Richard Thomas Marconi, Christopher G. Earnhart
-
Patent number: 9238065Abstract: The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polyoxypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA.Type: GrantFiled: April 27, 2012Date of Patent: January 19, 2016Assignee: ZOETIS SERVICES LLCInventors: Hsien-Jue Chu, Wumin Li, Zhichang Xu
-
Patent number: 9056909Abstract: Provided are immunogenic and vaccine compositions and methods for their preparation and use, which compositions are effective in protecting against, minimizing the severity of, preventing, and/or ameliorating M. hyopneumoniae infection. Administration to an animal of one or two doses of an adjuvanted live avirulent M. hyopneumoniae composition disclosed herein is effective in providing immunity to the animal and protection from infection with a virulent strain of M. hyopneumoniae thereby reducing the severity of and/or preventing disease caused by one or more virulent strain of M. hyopneumoniae. Also provided are compositions, which further comprise one or more antigen such as, for example, one or more live bacteria, bacterin, toxoid, and/or virus and/or viral antigen. Exemplified are immunogenic compositions, comprising an adjuvanted live avirulent M.Type: GrantFiled: November 5, 2008Date of Patent: June 16, 2015Assignee: Zoetis Services LLCInventors: Hsien-Jue Chu, Zhichang Xu, Wumin Li, Nicole Rae Gibson
-
Publication number: 20140314801Abstract: The instant invention provides an immunogenic composition comprising an antigenic fragment of OspA protein of Borrelia burgdorferi and a chimeric protein containing antigenic fragments of different phylotypes of OspC protein of Borrelia burgdorferi. Vaccines incorporating the immunogenic composition of the invention, as well as methods of preventing Lyme disease in dogs and/or protecting dogs from Lyme disease using the vaccines are also provided.Type: ApplicationFiled: April 17, 2013Publication date: October 23, 2014Inventors: Robert M. Lohse, Patrick F. M. Meeus, Jason J. Millership, Zhichang Xu
-
Publication number: 20120213816Abstract: The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polyoxypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA.Type: ApplicationFiled: April 27, 2012Publication date: August 23, 2012Inventors: Hsien-Jue Chu, Wumin Li, Zhichang Xu
-
Patent number: 8187588Abstract: The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polyoxypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA.Type: GrantFiled: January 22, 2010Date of Patent: May 29, 2012Assignee: Wyeth LLCInventors: Hsien-Jue Chu, Wumin Li, Zhichang Xu
-
Patent number: 7959927Abstract: The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosal and/or EDTA.Type: GrantFiled: November 16, 2009Date of Patent: June 14, 2011Assignee: Wyeth LLCInventors: Hsien-Jue Chu, Wumin Li, Zhichang Xu
-
Publication number: 20100119471Abstract: The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polyoxypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA.Type: ApplicationFiled: January 22, 2010Publication date: May 13, 2010Applicant: Wyeth LLCInventors: Hsien-Jue Chu, Wumin Li, Zhichang Xu
-
Publication number: 20100062018Abstract: The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably Carbopol, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polypropylene block copolymer such as Pluronic®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA.Type: ApplicationFiled: November 16, 2009Publication date: March 11, 2010Applicant: WyethInventors: Hsien-Jue Chu, Wumin Li, Zhichang Xu
-
Patent number: 7666439Abstract: The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polyoxypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA.Type: GrantFiled: August 21, 2006Date of Patent: February 23, 2010Assignee: Wyeth LLCInventors: Hsien-Jue Chu, Wumin Li, Zhichang Xu
-
Patent number: 7622124Abstract: The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA.Type: GrantFiled: January 11, 2007Date of Patent: November 24, 2009Assignee: WyethInventors: Hsien-Jue Chu, Wumin Li, Zhichang Xu